<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Assessment of tumor response in patients receiving systemic and nonsurgical locoregional treatment of hepatocellular cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shams I Iqbal, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keith E Stuart, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tracy Jaffe, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H88430730"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hepatocellular cancer (HCC) is an aggressive tumor that frequently occurs in the setting of underlying liver disease, particularly cirrhosis. The two factors that are most important in determining a patient's prognosis and potential treatment options are tumor mass/location and the patient's hepatic reserve. Patients with unresectable tumors who do not fulfill criteria for liver transplantation are typically managed with nonsurgical locoregional therapy (percutaneous needle-based ablation techniques, transarterial therapies, and/or radiation therapy [RT]) or systemic therapy (immune checkpoint inhibitors or molecularly targeted agents, such as <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> with <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> and <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>). (See  <a class="medical medical_review" href="/d/html/2488.html" rel="external">"Surgical resection of hepatocellular carcinoma", section on 'Preoperative assessment for resectability'</a> and  <a class="medical medical_review" href="/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma", section on 'Requirements for listing and management while on the wait list'</a>.)</p><p>The antitumor effect of many nonsurgical locoregional treatment modalities and many systemic therapies is not accurately reflected by conventional bidimensional tumor measurements on radiographic studies. Accurate assessment of response requires evaluation of tumor size and other features, including the ablative margin, tumor viability and vascularity (as reflected by contrast enhancement), and early detection of residual/recurrent tumor and new areas of tumor involvement.</p><p>This topic review will cover the alternative methods of tumor assessment used for HCC that is treated either by nonsurgical local means or systemic therapy. Antitumor efficacy of specific nonsurgical locoregional treatments and systemic therapy is covered elsewhere. (See  <a class="medical medical_review" href="/d/html/15589.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation"</a> and  <a class="medical medical_review" href="/d/html/2487.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates who are eligible for local ablation"</a> and  <a class="medical medical_review" href="/d/html/2486.html" rel="external">"Systemic treatment for advanced hepatocellular carcinoma"</a>.)</p><p class="headingAnchor" id="H849412"><span class="h1">TREATMENT ALGORITHMS AND GENERAL APPROACH TO THE PATIENT WITH HCC</span><span class="headingEndMark"> — </span>Treatments for HCC include potentially curative surgery (resection, liver transplantation), liver-directed therapies for unresectable liver-isolated disease in those ineligible for transplant, and systemic therapies:</p><p class="bulletIndent1"><span class="glyph">●</span>In general, the optimal treatment for early-stage HCC is surgical resection or liver transplantation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with unresectable tumors that are ineligible for liver transplantation are typically managed with nonsurgical locoregional therapy or systemic therapy. Nonsurgical locoregional therapy may also be used as a bridge to liver transplantation or to downstage tumors that initially exceed usual transplantation criteria in order to downstage them to possible candidacy for liver transplantation. (See  <a class="medical medical_review" href="/d/html/2488.html" rel="external">"Surgical resection of hepatocellular carcinoma"</a> and  <a class="medical medical_review" href="/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma", section on 'Requirements for listing and management while on the wait list'</a> and  <a class="medical medical_review" href="/d/html/2490.html" rel="external">"Liver transplantation for hepatocellular carcinoma", section on 'Bridging therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonsurgical locoregional therapies used for treatment of HCC include percutaneous needle-based ablation techniques, transarterial therapies, and radiation therapy (RT):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Image-guided percutaneous ablation is most appropriate for one or two tumors that are no larger than 4 cm. Methods include radiofrequency ablation (RFA), microwave ablation, cryoablation, percutaneous ethanol injection (PEI), irreversible electroporation, and high-intensity focused ultrasound (US) ablation. (See  <a class="medical medical_review" href="/d/html/2487.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates who are eligible for local ablation"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Arterially therapies can be used for patients who are not appropriate candidates for ablation; they include transarterial chemoembolization (TACE; includes both conventional and drug-eluting bead TACE), radioembolization (also termed selective internal RT), and bland embolization. (See  <a class="medical medical_review" href="/d/html/15589.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation"</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>External beam RT approaches include photon irradiation, stereotactic body RT (SBRT), and charged particle (eg, proton beam) irradiation. (See  <a class="medical medical_review" href="/d/html/15589.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation", section on 'Stereotactic body radiation therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Indications for systemic therapy are evolving. In general, systemic therapy is appropriate for patients with an acceptable performance status and underlying liver function who have extrahepatic spread, or have liver-limited disease that is refractory to nonsurgical locoregional therapies, or unsuitable for such therapies because of extensive vascular invasion or large intrahepatic tumor extent. (See  <a class="medical medical_review" href="/d/html/2486.html" rel="external">"Systemic treatment for advanced hepatocellular carcinoma"</a>.)</p><p></p><p>An algorithmic approach to the treatment of patients with HCC is shown in the figure  (<a class="graphic graphic_algorithm graphicRef57014" href="/d/graphic/57014.html" rel="external">algorithm 1</a>). An alternative treatment algorithm is available from Barcelona Clinic Liver Cancer group, which was updated in 2022  (<a class="graphic graphic_figure graphicRef139139" href="/d/graphic/139139.html" rel="external">figure 1</a>) [<a href="#rid1">1</a>]. However, attempts to generate algorithmic approaches to the treatment of HCC are difficult since new treatments and indications for various treatments are evolving rapidly. Furthermore, therapeutic approaches tend to vary based upon the available expertise, as well as variability in the criteria for hepatic resection and liver transplantation. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/2489.html" rel="external">"Overview of treatment approaches for hepatocellular carcinoma", section on 'Treatment algorithms'</a>.)</p><p class="headingAnchor" id="H524732010"><span class="h1">TECHNIQUES FOR ASSESSMENT OF TREATMENT RESPONSE</span><span class="headingEndMark"> — </span>Response assessment of HCC is a requirement for clinical evaluation of the effect of locoregional and systemic therapies, and for use as endpoints in clinical trials as a surrogate for survival. The gold standard for response to therapy is pathological evaluation of tissue. However, this is impractical as it is invasive and can have both false positive and false negative results, depending upon site of biopsy. Radiographic imaging offers a noninvasive, robust, and very accessible method of evaluation of tumor response.</p><p class="bulletIndent1"><span class="glyph">●</span>Typically, the efficacy of nonsurgical local ablation therapy is assessed by dynamic computed tomography (CT) or contrast-enhanced magnetic resonance imaging (MRI) one month after therapy and every three to six months thereafter. In general, MRI is preferred over CT due to its inherent superior tissue contrast resolution and sensitivity for detection of both the lesion and associated post-treatment changes. MRI is also beneficial for patients who have an allergy to iodinated contrast and for those who have undergone ethiodized oil (Lipiodol)-based therapies. (See <a class="local">'MRI'</a> below and <a class="local">'Response after locoregional therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients receiving systemic therapy, reimaging is typically carried out using cross-sectional imaging after the initial six to eight weeks of therapy, and then every two to three months thereafter. (See <a class="local">'Response to systemic therapy'</a> below.)</p><p></p><p>In either situation, for the subset of patients with an elevated alpha-fetoprotein (AFP), this marker can be useful to follow response; elevations may precede radiographic evidence of disease progression by several weeks or months. (See <a class="local">'Tumor markers'</a> below.)</p><p class="headingAnchor" id="H524732069"><span class="h2">Imaging studies</span><span class="headingEndMark"> — </span>Contrast-enhanced, cross-sectional imaging with MRI or CT is typically used for diagnosis of HCC and follow-up after therapy. There is no clear evidence of superiority of MRI over CT for assessing HCC response to therapy. MRI may be preferred for individuals with acute or chronic kidney injury, those who are allergic to intravenous iodinated contrast, and for follow-up of patients treated with Lipiodol-based conventional transarterial chemoembolization (TACE).</p><p class="headingAnchor" id="H524732075"><span class="h3">Computed tomography</span><span class="headingEndMark"> — </span>Contrast-enhanced CT is the most common radiographic modality used for diagnosis of HCC and follow-up after therapy. The ability of CT to detect HCC has improved with the development of helical CT technology, which involves the rapid administration of intravenous contrast in combination with extremely fast imaging. Multiphase contrast-enhanced thin-slice (multidetector row) helical CT (MDCT) is now the most common scanner type for CT evaluation. Thin section images allow multiplanar reconstruction, and the liver can be imaged in a single breath-hold, providing good quality images.</p><p>Attention must be paid to the type of scan that is ordered for treatment evaluation in patients with HCC. There is institutional variation in the scanning acquisitions for CT of post-treatment HCC. Some choose to add an unenhanced phase to characterize residual post-treatment enhancement. Routine imaging of HCC post treatment includes a single late arterial phase, a portal venous phase, and a late venous phase after iodinated contrast injection [<a href="#rid2">2</a>]. Standard single-phase CT with scanning during the portal venous phase is not generally sufficient to assess vascular characteristics associated with determining response.</p><p>The CT appearance of treated HCC is discussed in detail below. (See <a class="local">'Imaging appearance of treated HCC'</a> below.)</p><p class="headingAnchor" id="H524732206"><span class="h3">MRI</span><span class="headingEndMark"> — </span>Magnetic resonance imaging (MRI) is generally preferred over CT for assessing treatment response due to its inherent superior tissue contrast resolution and sensitivity for detection of both the lesion and associated post-treatment changes. Compared with CT, MRI has the advantage of achieving high-resolution images of the liver without the use of nephrotoxic contrast agents or ionizing radiation. On contrast-enhanced MRI, HCC appears as a moderately high-intensity pattern on T2-weighted images and a low intensity pattern on T1-weighted images precontrast, often with an enhancing capsule  (<a class="graphic graphic_diagnosticimage graphicRef75007" href="/d/graphic/75007.html" rel="external">image 1</a>). The characteristic appearance of HCC on contrast-enhanced MRI is arterial phase hyperenhancement, with subsequent washout on portal or delayed phases, lower signal intensity in the hepatobiliary phase (when gadoxetic acid is used), and capsular (pseudocapsule) enhancement.</p><p>Our institution uses the following protocol for liver evaluation on MRI: coronal fast spin echo T2-weighted images (which enhance T2 differences between tissues), axial fast spin echo T2-weighted images with and without chemical presaturation to reduce signal from fat (FAT-SAT), axial gradient recalled echo (GRE; which allows images to be acquired rapidly in a single breath-hold), in-phase and opposed-phase T1-weighted image, and axial three-dimensional FAT-SAT GRE T1-weighted imaging before and after dynamic injection of an extracellular gadolinium-based contrast agent (GBCA). (See  <a class="medical medical_review" href="/d/html/5309.html" rel="external">"Principles of magnetic resonance imaging"</a>.)</p><p>The volumetric T1-weighted imaging sequence is the most important sequence for HCC detection and characterization. Acquisitions are performed in the arterial, portal venous, late venous or equilibrium phase (three minutes after injection) and hepatobiliary phase at 10 or 20 minutes (for gadoxetic acid) [<a href="#rid3">3-5</a>].</p><p>The added value of liver-specific gadoxetic acid (Eovist) over extracellular GBCAs to assess response after locoregional therapy of HCC is unclear. One study suggested no benefit for the detection of local recurrence after RFA [<a href="#rid6">6</a>], whereas another study comparing CT with gadoxetic acid-enhanced MRI after RFA showed higher interobserver agreement and a better performance in general for MRI [<a href="#rid7">7</a>]. The added potential value of gadoxetic acid may be in the differentiation of small areas of viable tumor from "pseudolesions" seen during the arterial phase by assessing washout on the late venous phase or hypointensity in the hepatobiliary phase (which reflects the lack of functioning hepatocytes) [<a href="#rid8">8</a>]. However, the contrast kinetics of gadoxetic acid are such that the arterial phase lacks the robustness of gadolinium, and this may compromise the identification of new lesions.</p><p>For patients being assessed after nonsurgical ablation methods such as RFA or TACE, image subtraction techniques are used in every patient. This is helpful because without subtraction, post-treatment coagulative hemorrhagic necrosis tends to be bright on precontrast (unenhanced) T1-weighted imaging, leading to difficulty in evaluation of postcontrast tumor enhancement [<a href="#rid9">9</a>]. In addition, unlike CT, in which the beam-hardening effects of high-attenuation Lipiodol may obscure small enhancing tumors, Lipiodol does not adversely affect MRI signal-intensity characteristics, so residual enhancement can be detected, especially when image subtraction is used  (<a class="graphic graphic_diagnosticimage graphicRef99602" href="/d/graphic/99602.html" rel="external">image 2</a>) [<a href="#rid10">10,11</a>]. Contrast-enhanced dynamic T1-weighted imaging with diffusion-weighted MRI is a type of functional imaging that can also be advantageous in assessing treatment-related changes in HCC and is superior to contrast-enhanced CT after Lipiodol-based TACE therapies [<a href="#rid10">10,12,13</a>].</p><p>The MRI appearance of treated HCC and the Liver Reporting and Data System (LI-RADS) treatment response algorithm to assess response after locoregional therapies for HCC are discussed in detail below. (See <a class="local">'Response after locoregional therapy'</a> below.)</p><p>Diffusion-weighted imaging with MRI is a technique that derives its imaging contrast on the basis of differences in the mobility of extracellular protons in tissues. Diffusion is a physical process that results from the thermally driven random motion of water molecules. The signal of a diffusion-weighted MRI is proportional to the compactness of the cells, which in turn means a lack of extracellular space. This is exploited in interrogation of tumors to evaluate cellularity and cell death. This in turn can be an indirect measure of treatment effect. The diffusion characteristics are measured by the apparent diffusion coefficient. Most institutions do not routinely use diffusion-weighted imaging during MRI scans; however, it is increasingly being incorporated in routine protocols, especially for patients with renal insufficiency who cannot get intravenous contrast. There is some potential for diffusion-weighted imaging for monitoring the response to anti-HCC treatment, but this is not yet a standard approach [<a href="#rid14">14</a>]. (See <a class="local">'Functional imaging'</a> below.)</p><p class="headingAnchor" id="H569153335"><span class="h3">Other imaging studies</span></p><p class="headingAnchor" id="H524732743"><span class="h4">Ultrasound</span><span class="headingEndMark"> — </span>In general, ultrasound (US) is used for HCC screening and is not used for follow-up imaging after locoregional or systemic treatment of HCC. US is limited by lower sensitivity, inability to distinguish viable versus nonviable tumors, and its operator dependency. </p><p class="headingAnchor" id="H3973298775"><span class="h4">Dual energy/dual source CT</span><span class="headingEndMark"> — </span>The use of dual energy/dual source CT (DECT) is not established, and further studies are necessary prior to incorporating this approach into routine clinical practice. Dual energy CT scanners are also not universally available across imaging practices.</p><p>DECT is a technology in which images are acquired by using two different energy beams that can be from two different sources in the same gantry, or by alternating high- and low-energy radiation from the same source at high speed. DECT provides a higher temporal resolution and can provide an iodine map with virtual nonenhanced images, which decreases radiation dose as it eliminates the need for nonenhanced image acquisition.</p><p>DECT increases detection of hypervascular lesions, such as HCC, and it may improve characterization of indeterminate subcentimeter lesions [<a href="#rid15">15,16</a>]. DECT may also have utility in evaluating HCC response to locoregional therapy, such as radiofrequency ablation (RFA), because of a higher lesion-to-liver contrast-to-noise ratio on iodine maps, aiding in the detection of residual tumor [<a href="#rid17">17</a>]. </p><p class="headingAnchor" id="H524732851"><span class="h2">Tumor markers</span></p><p class="headingAnchor" id="H524734479"><span class="h3">AFP</span><span class="headingEndMark"> — </span>In the subset of patients with an elevated alpha-fetoprotein (AFP), this marker can be useful to follow response to nonsurgical locoregional therapies and provide an early screening test for progression, which should later be confirmed by imaging [<a href="#rid18">18-20</a>]. In most, but not all [<a href="#rid21">21</a>], studies, serial measurements of AFP appear to be a valid surrogate endpoint for benefit from systemic chemotherapy, including molecularly targeted agents [<a href="#rid22">22-29</a>]. In one study, AFP responders (arbitrarily defined as patients whose serum AFP decreased by more than 20 percent after a minimum of two cycles of chemotherapy) had better median survival than did nonresponders (13.5 versus 5.6 months), and AFP response was strongly associated with radiographic response [<a href="#rid23">23</a>]. Furthermore, an AFP response was frequently observed in patients with radiographically stable disease and served to identify a subgroup of these patients with better survival.</p><p>Unfortunately, AFP levels are not elevated in up to 40 percent of patients with HCC &lt;2 cm in diameter and in 28 percent of those with tumors between 2 and 5 cm. (See  <a class="medical medical_review" href="/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Alpha-fetoprotein'</a>.)</p><p class="headingAnchor" id="H600604291"><span class="h3">DCP</span><span class="headingEndMark"> — </span>Use of an alternative tumor marker, des-gamma-carboxy prothrombin (DCP), has been suggested in patients with advanced HCC, but the available data suggest that DCP levels do not always correlate with survival after treatment with either locoregional or systemic therapies [<a href="#rid30">30-34</a>], and it is not clear that DCP adds value to monitoring serum levels of AFP when both markers are elevated. Furthermore, serum assay for DCP is not widely available. The utility of DCP for screening and diagnosis of HCC is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3597.html" rel="external">"Clinical features and diagnosis of hepatocellular carcinoma", section on 'Other markers'</a>.)</p><p class="headingAnchor" id="H524734502"><span class="h3">Plasma VEGF levels</span><span class="headingEndMark"> — </span>Changes in circulating plasma vascular endothelial growth factor (VEGF) may represent a novel prognostic marker for HCC; a staging system has been proposed that includes plasma VEGF concentration along with the Cancer of the Liver Italian Program (CLIP) score (V-CLIP score). (See  <a class="medical medical_review" href="/d/html/2476.html" rel="external">"Staging and prognostic factors in hepatocellular carcinoma", section on 'New prognostic markers and methods under investigation'</a>.)</p><p>Plasma VEGF levels may represent a surrogate marker for benefit from <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, an inhibitor of multiple receptor kinases including the VEGF receptor, but the available data are conflicting:</p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective review of 63 patients with advanced HCC, a decrease in plasma VEGF levels of &gt;5 percent from the pretreatment baseline at eight (but not four) weeks after initiating <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> was associated with significantly longer median overall survival compared with patients without a 5 percent decrease (30.9 versus 14.4 months) [<a href="#rid35">35</a>]. While intriguing, this evaluation is based upon a very small number of patients (n = 14) with a &gt;5 percent decrease in serum VEGF at eight weeks, and additional data are needed to confirm and validate these findings.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, an analysis of data from a pivotal phase III trial that established the survival benefit of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> in advanced HCC failed to find an association between plasma biomarkers, including VEGF, and outcomes [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H3484792822"><span class="h3">Liquid biopsy analysis</span><span class="headingEndMark"> — </span>Liquid biopsies, or blood samples, can be analyzed to detect circulating tumor cells and plasma cell-free circulating tumor DNA (ctDNA), but whether these assays aid in prognostication or response classification is unclear:</p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review of 112 studies, including 25 that focused on treatment monitoring or selection, concluded that changes in numbers of circulating tumor cells could more accurately identify patients with an HCC recurrence after resection or locoregional therapy than pretreatment counts alone [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Few studies have examined the effect of post-treatment ctDNA on prognosis, and most have generally failed to show an association with progression-free survival (PFS) or overall survival [<a href="#rid38">38,39</a>]. One notable exception is that among patients treated with first-line <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>, at least one preliminary report noted that longer PFS was observed in patients whose ctDNA became undetectable post-treatment, although the confidence intervals were wide [<a href="#rid40">40</a>]. The median PFS in patients with ctDNA present versus cleared at C4D1 was 6.5 months and not reached, respectively (HR for progression 12.0 [95% CI 1.7-93], log-rank p &lt;0.00029).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition, of the several studies evaluating changes in ctDNA after therapy, at least three found that changes in ctDNA preceded radiographic documentation of tumor progression by up to eight weeks [<a href="#rid40">40-42</a>]. However, the lack of assay standardization and high risk of bias complicates interpretation of these studies. The clinical utility of liquid biopsy analysis in management of patients with HCC remains uncertain.</p><p></p><p class="headingAnchor" id="H2450116958"><span class="h1">IMAGING APPEARANCE OF TREATED HCC</span></p><p class="headingAnchor" id="H3552938835"><span class="h2">Response after locoregional therapy</span><span class="headingEndMark"> — </span>Imaging performed immediately after locoregional therapy can aid in evaluation of the treatment and act as a guide to expected outcomes. Although not entirely reliable, the absence of contrast uptake within the tumor is thought to reflect tumor necrosis, while the persistence of contrast uptake generally indicates persistent disease. Recurrence of tumor in the treated area (or elsewhere) is signaled by the reappearance of vascular enhancement. </p><p class="bulletIndent1"><span class="glyph">●</span>When treating HCC with transarterial chemoembolization (TACE) using ethiodized oil (Lipiodol), unenhanced computed tomography (CT) can be performed immediately to assess Lipiodol distribution. In general, complete retention of iodized oil is highly correlated with complete lesion necrosis, while incomplete retention may represent complete necrosis or residual viable tumor [<a href="#rid43">43,44</a>]. If unenhanced CT shows lack of Lipiodol uptake within the tumor, this likely represents arteriovenous shunting through the tumor or a variant tumor vascular supply (including one that may be extrahepatic), and that tumor will likely require retreatment [<a href="#rid45">45</a>].</p><p></p><p class="bulletIndent1">The iodized oil is not apparent on magnetic resonance imaging (MRI), and thus, MRI is generally preferred to assess for recurrent/viable tumor over time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To assess for technical success after selective internal radiation therapy (SIRT), the patient is immediately transferred to the nuclear medicine department for a single-photon emission computed tomography (SPECT) scan, which shows the distribution of yttrium-90 (Y90) in the liver. Some institutions perform Y90 positron emission tomography/CT and Bremsstrahlung SPECT/CT to evaluate the distribution of radiation dose with proprietary software showing the distribution of treatment across the tumor and assessing need of retreatment [<a href="#rid46">46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After ablation (radiofrequency ablation [RFA], microwave, cryoablation), immediate success is defined as a nonenhancing ablation zone encompassing the entire tumor and an ablative safety margin of at least 5 mm of the surrounding nontumor hepatic parenchyma [<a href="#rid47">47</a>]. Following RFA, gas bubbles can form as a result of treatment and should not be mistaken for infection or infarction [<a href="#rid48">48</a>].</p><p></p><p>A thin, uniform rim of enhancement around the treated zone that reflects transient hyperemia and represents a physiologic response to thermal injury, and embolization of the hepatic parenchyma can be seen after RFA, TACE, or SIRT [<a href="#rid49">49</a>]. This usually resolves within several months of follow-up imaging, a fact that permits it to be differentiated from residual malignancy [<a href="#rid50">50</a>]. However, small foci of residual tumor may be obscured by transient hyperemia; cases showing persistent arterial enhancement with washout on delayed phase images at short-term follow-up should be evaluated further to determine whether additional directed therapy is needed [<a href="#rid49">49</a>].</p><p>Analysis of enhancement patterns on the arterial phase of the first follow-up CT is helpful for predicting progression of treated HCC. Regardless of the mode of therapy, nodular or thick areas of arterial enhancement along the margin of a treated HCC are consistent with residual tumor, especially when there is associated contrast washout. This treatment response is categorized as LI-RADS TR-viable  (<a class="graphic graphic_algorithm graphicRef130552" href="/d/graphic/130552.html" rel="external">algorithm 2</a>); in general, these are areas that require additional treatment  (<a class="graphic graphic_diagnosticimage graphicRef100103" href="/d/graphic/100103.html" rel="external">image 3</a>) [<a href="#rid48">48,51</a>]. </p><p>Radiologic patterns after treatment vary according to treatment modality:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ablative therapy</strong> – At short-term follow-up, coagulative necrosis, as induced by locoregional ablative therapies, appears as hyperdensity on CT and high signal intensity on T1-weighted MRI. Both of these changes limit the evaluation of contrast-enhanced images, which are of paramount importance to evaluate the efficacy of treatment, given that residual enhancement implies residual tumor. This can be circumvented by the use of image subtraction on MRI, which is helpful in differentiating coagulative necrosis, hemorrhage, and residual enhancing tumor  (<a class="graphic graphic_diagnosticimage graphicRef99602" href="/d/graphic/99602.html" rel="external">image 2</a>). (See <a class="local">'MRI'</a> above.)</p><p></p><p class="bulletIndent1">This problem is most often seen on the one-month post-treatment images. The hyperdensity on CT and increased T1 signal in the treated area resulting from coagulative necrosis frequently resolve on further follow-up imaging [<a href="#rid50">50</a>]. For this reason (and to reduce exposure to ionizing radiation), we prefer MRI over CT at the one-month time point.</p><p></p><p class="bulletIndent1">Following ablation therapy, residual viable tumor or tumor regrowth is most often detected at the periphery of the treated lesion, either as irregular thickening at the margin or as a new tumor nodule  (<a class="graphic graphic_diagnosticimage graphicRef99603" href="/d/graphic/99603.html" rel="external">image 4</a>) [<a href="#rid52">52</a>]. By MRI, increased signal intensity on T2-weighted imaging or restriction on diffusion-weighted MRI with associated nodular enhancement is characteristic of an incompletely treated tumor. If HCC is ablated using RFA, arterioportal shunts can be seen due to thermal injury to small vessels in the hepatic parenchyma but will resolve on follow-up evaluation [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TACE</strong> – For patients treated with TACE using drug-eluting beads (DEB-TACE) or conventional TACE (cTACE) containing Lipiodol, follow-up contrast-enhanced CT or MRI should be performed to assess areas lacking enhancement [<a href="#rid43">43</a>]. Areas that increase in size over time or develop arterial enhancement after contrast injection  (<a class="graphic graphic_diagnosticimage graphicRef100103" href="/d/graphic/100103.html" rel="external">image 3</a>) should raise suspicion for recurrent disease. cTACE using Lipiodol can lead to interference with CT; however, this is not an issue with DEB-TACE. In general, MRI is more useful in comparison with CT in cTACE setting because of the lack of interference of Lipiodol and the use of subtraction images to evaluate for residual/recurrent disease [<a href="#rid11">11</a>]. Because of this, many centers now utilize DEB- rather than Lipiodol-TACE, and in these instances MRI with contrast, or multiphasic CT would be most useful for response evaluation. (See <a class="local">'MRI'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiation-based treatments</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>TARE</strong> – In general, patients treated with transarterial radioembolization (TARE) have a delayed tumor response; the median time to develop evidence of necrosis (decreased enhancement) and tumor shrinkage is approximately 30 and 120 days, respectively [<a href="#rid54">54</a>]. Because of this, we perform our first radiographic assessment for disease response at three months.</p><p></p><p class="bulletIndent2">As with other ablative locoregional therapies, rim contrast enhancement can persist over time and is not indicative of viable tumor; in one radiologic-pathologic correlation study, complete pathologic necrosis was seen in 93 percent of the cases with thin rim enhancement on post-treatment imaging, while complete pathologic necrosis was seen in only 38 percent of the lesions that showed peripheral nodular enhancement [<a href="#rid55">55,56</a>]. Enhancement patterns after TARE are highly variable. Heterogeneous enhancement of the liver in a perivascular distribution in a treated segment or lobe reflects radiation injury and should not be mistaken for tumor progression  (<a class="graphic graphic_diagnosticimage graphicRef99604" href="/d/graphic/99604.html" rel="external">image 5</a>) [<a href="#rid55">55,57</a>]. This is particularly a problem with the Liver Reporting and Data System (LI-RADS) treatment response algorithm. Key features suggesting residual tumor after TARE includes a new or enlarging nodular or mass-like area of arterial phase hyperenhancement within or around the treated tumor, and growth over time [<a href="#rid58">58</a>]. (See <a class="local">'LI-RADS algorithm'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>EBRT and</strong> <strong>SBRT</strong> – Patients treated with external beam radiotherapy (EBRT), including hypofractionated stereotactic body radiation therapy (SBRT) also have a delayed tumor response, with persisting arterial phase hyperenhancement with or without washout for a year or more, followed by gradual decrease over time [<a href="#rid58">58,59</a>]. In one report, radiographic "complete response" rates at 3, 6, and 12 months post-treatment were 24, 67, and 71 percent, respectively [<a href="#rid60">60</a>]. Furthermore, irradiated nontumorous hepatic parenchyma may also show arterial hypervascularity after treatment, and this might interfere with the evaluation of treatment response on dynamic cross-sectional imaging [<a href="#rid61">61</a>]. These issues create diagnostic dilemma during image interpretation, particularly using the LI-RADS treatment response algorithm, because persistent arterial enhancement, while expected post-treatment, denotes viable disease in the setting of other locoregional therapies. (See <a class="local">'LI-RADS algorithm'</a> below.)</p><p></p><p class="bulletIndent2">In our experience, these findings are usually equivocal and a decision for further treatment is usually deferred until the six-month scan. At our institution, we prefer MRI over CT unless there is a contraindication for MRI. MRI is generally more helpful than CT in this setting, although difficulties remain with differentiating residual arterial enhancement from radiation changes. In general, these distinctions become clearer with time, usually greater than three months.</p><p></p><p class="headingAnchor" id="H2556498205"><span class="h2">Response to systemic therapy</span><span class="headingEndMark"> — </span>Early assessment of response to molecularly targeted therapies including tyrosine kinase inhibitors (TKIs) can be challenging since tumor necrosis, extension, and radiologic appearance can be inhomogeneous, and radiologic response rates are very low [<a href="#rid62">62-65</a>]. As with locoregional therapies, residual or progressive thick and nodular foci of arterial enhancement within HCC suggest persistent or progressing viable tumor. In clinical practice, efficacy for molecularly targeted agents like TKIs tends to be measured in lack of progression rather than true radiologic "response." (See  <a class="medical medical_review" href="/d/html/2486.html" rel="external">"Systemic treatment for advanced hepatocellular carcinoma", section on 'Response assessment'</a> and  <a class="medical medical_review" href="/d/html/2486.html" rel="external">"Systemic treatment for advanced hepatocellular carcinoma", section on 'First-line therapy'</a>.)</p><p>Notably, an increase in tumor size due to necrosis has been reported in patients treated with multikinase inhibitors, such as <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a>, a phenomenon referred to as "pseudoprogression" [<a href="#rid21">21</a>]. Therefore, quantification of necrosis/tumor viability rather than size measurement appears to be a better method of treatment response assessment in HCC treated with these biologic agents [<a href="#rid21">21,62</a>]. (See <a class="local">'Measuring tumor dimensions versus tumor viability'</a> below.)</p><p>For patients treated with checkpoint inhibitor immunotherapy, patterns of response to treatment differ from those with molecularly targeted agents. Patients may appear to have a transient worsening of disease, manifested either by progression of known lesions or the appearance of new lesions, before disease stabilizes or regresses, and responses may be delayed. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Patterns of response'</a>.)</p><p>Immune-related response criteria have been proposed to properly recognize the nontraditional patterns of response occasionally seen with checkpoint inhibitors and some other immunotherapies. Pseudoprogression has also been reported with immune checkpoint inhibitors. Issues specific to assessing response to immunotherapy are addressed below. (See <a class="local">'Response criteria for immunotherapy'</a> below.)</p><p class="headingAnchor" id="H436793092"><span class="h1">CRITERIA FOR RESPONSE ASSESSMENT</span><span class="headingEndMark"> — </span>In patients with advanced HCC who have completed therapy (either nonsurgical locoregional or systemic therapy), various classification systems are used to assess treatment response. </p><p>For patients treated with systemic therapy, treatment response is typically classified using either the modified Response Evaluation Criteria In Solid Tumor for HCC (mRECIST)  (<a class="graphic graphic_table graphicRef58792" href="/d/graphic/58792.html" rel="external">table 1</a>), or RECIST  (<a class="graphic graphic_table graphicRef74693" href="/d/graphic/74693.html" rel="external">table 2</a>). Patients treated with immunotherapy are assessed using consensus based criteria for response to immunotherapy (iRECIST)  (<a class="graphic graphic_table graphicRef115573" href="/d/graphic/115573.html" rel="external">table 3</a>). For patients treated with locoregional therapy, treatment response is classified using LI-RADS  (<a class="graphic graphic_algorithm graphicRef130552" href="/d/graphic/130552.html" rel="external">algorithm 2</a>). </p><p class="headingAnchor" id="H2149316356"><span class="h2">Measuring tumor dimensions versus tumor viability</span><span class="headingEndMark"> — </span>Anatomic measurements of tumor dimension before and after treatment is one radiographic method to assess treatment response. A decrease in tumor size is often used as a surrogate endpoint to predict survival outcome in patients undergoing systemic treatment for a variety of solid tumors [<a href="#rid66">66-68</a>]. Tumor size is still an important parameter in measuring treatment response to HCC, and there is evidence that the more rapidly a tumor shrinks, the more durable the response. For advanced HCC, response criteria based on tumor dimension include the World Health Organization (WHO) [<a href="#rid69">69</a>] and RECIST 1.1. (See <a class="local">'Response Evaluation Criteria In Solid Tumor (RECIST)'</a> below.)</p><p>However, the antitumor effect of many nonsurgical locoregional and systemic therapies, (such as antiangiogenic multikinase inhibitors and immune checkpoint inhibitors) is not always accurately reflected by changes in tumor dimension [<a href="#rid70">70-73</a>]. Such measurements do not incorporate tumor viability and the extent of necrosis resulting from locoregional ablative therapies, such as transarterial chemoembolization (TACE) [<a href="#rid72">72</a>] or systemic therapy with antiangiogenic therapy. Necrosis may be associated with no change in the lesion size, or it may precede a change in measurable dimensions [<a href="#rid73">73</a>]. (See <a class="local">'Response criteria for immunotherapy'</a> below.)</p><p>This led to the development of criteria that classify tumor response for HCC based on tumor viability, including tumor necrosis, the ablative margin, and lesion vascularity (as reflected by contrast enhancement). Criteria have evolved from those that utilize only bidimensional measurements to those that evaluate the post-treatment changes on contrast-enhanced cross-sectional imaging scans (such as mRECIST for HCC and LI-RADS). (See <a class="local">'Modified RECIST for HCC'</a> below and <a class="local">'LI-RADS algorithm'</a> below.)</p><p>Response criteria that assess tumor viability are typically preferred over those based on tumor dimension. Using contrast-enhanced cross-sectional imaging, the absence of contrast uptake within the tumor is thought to reflect tumor necrosis, while the persistence of contrast uptake indicates persistent disease. Recurrence of tumor in the treated area (or elsewhere) is signaled by the reappearance of vascular enhancement. Most (but not all [<a href="#rid30">30,74,75</a>]) studies support the view that classifications systems of tumor response to both systemic and nonsurgical locoregional treatments for HCC according to tumor viability are a better predictor of outcomes compared with those that use tumor size alone [<a href="#rid76">76-83</a>].</p><p class="headingAnchor" id="H3732942570"><span class="h2">Following systemic therapy</span><span class="headingEndMark"> — </span>Response assessment criteria are available that are applicable to systemic therapies, although some may also be used to assess treatment response with nonsurgical liver-directed therapies.</p><p class="headingAnchor" id="H3793846153"><span class="h3">Modified RECIST for HCC</span><span class="headingEndMark"> — </span>In 2000, a panel of experts convened by the EASL recommended a modification of the Response Evaluation Criteria In Solid Tumor (RECIST) criteria to take into account tumor necrosis induced by HCC treatment, whether locoregional or systemic [<a href="#rid84">84</a>]. The panel adopted the concept of viable tumor (defined as uptake of contrast agent in the arterial phase of dynamic CT or MRI) as endorsed by the EASL [<a href="#rid85">85</a>] and the American Association for the Study of Liver Disease [<a href="#rid84">84</a>], and proposed amendments to RECIST criteria for the determination of tumor response for target lesions in HCC, termed the mRECIST for HCC  (<a class="graphic graphic_table graphicRef58792" href="/d/graphic/58792.html" rel="external">table 1</a>) [<a href="#rid86">86</a>]. (See <a class="local">'Response Evaluation Criteria In Solid Tumor (RECIST)'</a> below.)</p><p>The expert panel emphasized the importance of standardization of response assessment, definition of treatment response and tumor progression, and overall response assessment [<a href="#rid84">84,86</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Standardized response assessment</strong> – The key to proper application of mRECIST for HCC is optimization of image acquisition protocol and consistent use of the same protocol for response assessment throughout follow-up evaluation. Modality-wise, either CT or MRI can be used. Intravenous contrast administration is recommended unless medically contraindicated. Dual phase imaging is mandatory, including arterial and portal venous phase. Delayed phase imaging is not mandatory. Multidetector CT acquiring thin, contiguous slices with no reconstruction gap is mandatory. For image interpretation, the panel recommended a "centralized radiologic review" to ensure comparability across studies. Uniform image acquisition parameters, rigorous quality control, and independent blinded multireader assessment are mandatory. Independent radiologists will assess the baseline imaging and follow-up imaging according to mRECIST.</p><p></p><p class="bulletIndent1">At baseline, tumors are characterized as measurable (lesion accurately measured in at least one dimension equal to or greater than 1 cm) or nonmeasurable (all other lesions, lesions smaller than 1 cm). Importantly, mRECIST for HCC criteria can only be used for typical hypervascular HCC and not for atypical HCC, including poorly differentiated HCC and diffuse-type HCC. For these nonenhancing atypical lesions, standard RECIST criteria are used  (<a class="graphic graphic_table graphicRef74693" href="/d/graphic/74693.html" rel="external">table 2</a>). HCC lesions that were treated in the past with locoregional or systemic treatments may or may not be considered suitable targets for mRECIST for HCC; if the lesion shows a well-defined area of arterial enhancement, which correlates with viable tumor, and is at least 1 cm in the longest dimension, it can be considered a target lesion. Lesions showing atypical enhancement with poor delineation due to prior treatment cannot be selected for mRECIST for HCC evaluation.</p><p></p><p class="bulletIndent1">Lesions that can be selected as a target lesion as per mRECIST for HCC should meet the following criteria:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>They can be classified as a RECIST measurable lesion</p><p class="bulletIndent2"><span class="glyph">•</span>They are suitable for repeat measurement</p><p class="bulletIndent2"><span class="glyph">•</span>They show intratumoral arterial enhancement on contrast-enhanced CT or MRI</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definitions of treatment response and tumor progression</strong> – As outlined in the table, these are classified as target lesion response, nontarget lesion response, and new lesions  (<a class="graphic graphic_table graphicRef58792" href="/d/graphic/58792.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">Target lesion response is classified as complete response, partial response, progressive disease, and stable disease.</p><p></p><p class="bulletIndent1">Following treatment, likely due to necrosis, viable tumor measurement can be a challenge. Arterial phase measurement of CT or MRI was recommended since the contrast between the viable and nonenhancing necrotic area is highest at this time. Measure the longest diameter of viable tumor without any intervening major area of necrosis. It should be mentioned that the longest diameter of enhancement on post-treatment scans may not be in the same plane as the baseline measurement. The panel mentioned that volumetric assessment should be a priority for future research, since there is a 138 percent difference in tumor volume between partial response (at least a 30 percent decrease in the sum of the diameters of the target lesions, amounting to a 65 percent change in volume) and progressive disease (increase of at least 20 percent in the diameter of the viable tumor, amounting to a 73 percent change in volume).</p><p></p><p class="bulletIndent1">For nontarget lesions, persistent enhancement in even one lesion should be considered an incomplete response or stable disease, and a lack of contrast enhancement is consistent with a complete response. Appearance of even one new lesion or unequivocal progression of the older nontarget lesion should be called progressive disease. Some nontarget lesions (eg, malignant portal vein thrombus) are considered nonmeasurable. For a porta hepatis lymph node to be considered malignant, it should measure at least 20 mm in the short axis. In patients showing worsening of ascites or pleural effusion who have otherwise met criteria of response or stable disease, the nature of ascites/pleural effusion should be confirmed by cytopathology.</p><p></p><p class="bulletIndent1">A newly detected hepatic nodule is classified as HCC (and declared evidence of progression) when its longest diameter is at least 1 cm and the nodule has a typical vascular pattern on dynamic imaging (hypervascular in arterial phase with washout in the portal venous or late venous phase). Liver lesions &gt;1 cm that do not show a typical vascular pattern can be diagnosed as HCC if there is at least 1 cm of interval growth on subsequent scans. An individual radiologic event will be called disease progression in retrospect at the time the lesion was first detected, even if the lesion formally fulfilled the criteria for disease progression only on subsequent imaging scans.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overall response assessment</strong> – Similar to conventional RECIST, mRECIST defines overall patient response as a result of the combined assessment of the target lesions, nontarget lesions, and new lesions  (<a class="graphic graphic_table graphicRef58792" href="/d/graphic/58792.html" rel="external">table 1</a>). Appearance of any new lesion equates to disease progression, irrespective of the target and nontarget lesions' response to therapy. Thus, strict criteria should be enforced, and any lesion not meeting strict criteria should be considered equivocal and not conclusive for disease progression.</p><p></p><p class="bulletIndent1">Although data are limited, a preliminary report from the IMbrave150 trial of <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> plus a report from the REFLECT trial of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a> for systemic treatment of HCC both support the view that decreases in tumor size as assessed by mRECIST represent a surrogate endpoint to predict survival outcome in patients undergoing systemic treatment for HCC using these agents [<a href="#rid87">87-89</a>]. (See  <a class="medical medical_review" href="/d/html/2486.html" rel="external">"Systemic treatment for advanced hepatocellular carcinoma", section on 'Sorafenib'</a> and  <a class="medical medical_review" href="/d/html/2486.html" rel="external">"Systemic treatment for advanced hepatocellular carcinoma", section on 'Lenvatinib'</a>.)</p><p></p><p class="headingAnchor" id="H621502373"><span class="h3">Response Evaluation Criteria In Solid Tumor (RECIST)</span><span class="headingEndMark"> — </span>RECIST 1.1 represents the most widely used criteria for response assessment in solid tumors  (<a class="graphic graphic_table graphicRef57181" href="/d/graphic/57181.html" rel="external">table 4</a>). </p><p>Anatomic criteria, such as RECIST, are still used in virtually every clinical trial of HCC therapeutics as bidimensional measurements of response on imaging are essentially always measured. Furthermore, in many countries, regulatory agencies use RECIST as the standard response assessment criteria in clinical trials of HCC; alternative methods of response assessment (eg, mRECIST for HCC) have not yet achieved widespread adoption.</p><p>Standard RECIST 1.1 guidelines are also used for nonenhancing atypical lesions, including poorly differentiated HCC and diffuse-type HCC. Radiographic response criteria that assess tumor viability cannot be used for atypical HCC. </p><p class="headingAnchor" id="H266816838"><span class="h3">Response criteria for immunotherapy</span><span class="headingEndMark"> — </span>Immunotherapy for HCC is a rapidly evolving area of treatment in advanced HCC. The combinations of <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> plus <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a> and <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a> plus <a class="drug drug_general" data-topicid="139983" href="/d/drug information/139983.html" rel="external">tremelimumab</a> are now preferred first-line regimens over treatment with a molecularly targeted agent such as <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> or <a class="drug drug_general" data-topicid="99962" href="/d/drug information/99962.html" rel="external">lenvatinib</a>. (See  <a class="medical medical_review" href="/d/html/2486.html" rel="external">"Systemic treatment for advanced hepatocellular carcinoma", section on 'Atezolizumab plus bevacizumab'</a>.)</p><p>The patterns of response to treatment with immunotherapy differ from those with molecularly targeted agents or cytotoxic chemotherapy. As an example, in early trials of immunotherapy in melanoma, a unique response pattern was seen, termed "pseudoprogression," in which patients appear to have a transient worsening of disease, manifested either by progression of known lesions or the appearance of new lesions, before disease stabilizes or regresses. In addition, responses can take appreciably longer to become apparent compared with cytotoxic therapy. These issues are all addressed elsewhere. (See  <a class="medical medical_review" href="/d/html/99637.html" rel="external">"Principles of cancer immunotherapy", section on 'Patterns of response'</a>.)</p><p>In clinical practice, patients receiving any immune-based therapy for advanced HCC whose tumors show initial growth should be assessed carefully for signs and symptoms of clinical benefit or progression; the majority of patients will have true progressive disease. In the absence of symptomatic progression, however, a short-term repeat scan is reasonable prior to considering immune-based therapy a failure.</p><p>Accumulating data suggest that on-treatment AFP changes over time can complement imaging findings and provide prognostic information for AFP-producing HCCs treated with immune checkpoint inhibitor immunotherapy [<a href="#rid90">90-93</a>].</p><p class="headingAnchor" id="H2353132431"><span class="h3">Other criteria</span><span class="headingEndMark"> — </span>The European Association for the Study of the Liver (EASL) criteria are not routinely used to measure treatment response in HCC [<a href="#rid85">85</a>]. These criteria incorporated estimated bidimensional reductions in viable tumor burden using dynamic imaging into response definitions. The most important limitation is the lack of guidelines regarding the choice of target lesions (number and size of measurable lesions). These criteria have fallen out of favor since the publication of the mRECIST in HCC criteria, which is endorsed by most of the leading groups in the field of HCC management. (See <a class="local">'Modified RECIST for HCC'</a> above.)</p><p class="headingAnchor" id="H404891674"><span class="h2">Following nonsurgical locoregional therapies</span><span class="headingEndMark"> — </span>The antitumor effect of many nonsurgical locoregional treatment modalities for HCC is not accurately reflected by conventional bidimensional radiographic tumor measurements. Accurate radiographic assessment of response following nonsurgical locoregional treatment requires evaluation of residual tumor enhancement after therapy. Furthermore, the treatment response classification systems described above are based on tumor response assessment at the patient level rather than at the lesion level. For individual therapies that target specific lesions (eg, radiofrequency or microwave ablation), this may not provide a suitable assessment of treatment outcomes. (See  <a class="medical medical_review" href="/d/html/2487.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates who are eligible for local ablation"</a> and  <a class="medical medical_review" href="/d/html/15589.html" rel="external">"Localized hepatocellular carcinoma: Liver-directed therapies for nonsurgical candidates not eligible for local thermal ablation"</a>.)</p><p>Assessment of treatment response after nonsurgical local therapies should be performed with multiphase, contrast-enhanced, cross-sectional imaging (CT with iodinated contrast or MRI with gadolinium-based agents). MRI is the preferred imaging modality with a sensitivity and specificity for lesion detection of 88 and 94 percent, respectively [<a href="#rid94">94</a>]. Furthermore, in patients undergoing locoregional therapy, contrast-enhanced MRI is more sensitive than CT for evaluating tumor viability using the LI-RADS treatment response algorithm [<a href="#rid95">95</a>]. (See <a class="local">'LI-RADS algorithm'</a> below.)</p><p>As tumor enhancement characteristics post-therapy are essential in assessment for tumor viability [<a href="#rid96">96</a>], contrast should be administered unless there are contraindications. Patients with iodinated contrast allergies should be routed to MRI and those with gadolinium allergies to CT. Preexisting kidney impairment is not considered a contraindication for contrast-enhanced MRI [<a href="#rid97">97</a>].</p><p class="headingAnchor" id="H3356374253"><span class="h3">LI-RADS algorithm</span><span class="headingEndMark"> — </span>The American College of Radiology has developed the Liver Reporting and Data System (LI-RADS) treatment response algorithm after locoregional therapies for HCC  (<a class="graphic graphic_algorithm graphicRef130552" href="/d/graphic/130552.html" rel="external">algorithm 2</a>) [<a href="#rid96">96,98</a>]. The most important feature of this treatment response algorithm is persistent lesion contrast enhancement and washout. These same characteristics are used for early detection of residual/recurrent tumor and new areas of tumor involvement. Using the LI-RADS treatment response algorithm, tumors are categorized as viable, nonviable, or equivocal [<a href="#rid58">58,96</a>]. The absence of contrast uptake within the tumor reflects nonviable tumor, while the persistence of contrast uptake indicates persistent disease, referred to as viable. If a tumor has enhancement atypical for treatment, it is deemed equivocal. Recurrence of tumor in the treated area (or elsewhere) is signaled by the reappearance of vascular enhancement or nodular, mass-like, or thick irregular tissue in or along the treated lesion.</p><p>An important point is that LI-RADS provides guidelines only to identify viable tissue, and not to classify changes over time. An integration of LI-RADS with mRECIST for HCC could be necessary for best response evaluation over time.</p><p>LI-RADS is best suited to evaluate response to nonradiation arterial and ablation procedures, in which tumor necrosis is expected immediately after locoregional therapy. It should be applied only cautiously to patients undergoing stereotactic body radiation therapy and selective internal radiation therapy in which tumor necrosis develops over time, and early post-treatment persistent arterial phase hyperenhancement is common, expected, and can confound the assessment of treatment response. (See <a class="local">'Response after locoregional therapy'</a> above.)</p><p class="headingAnchor" id="H524734847"><span class="h2">Future trends</span></p><p class="headingAnchor" id="H524734624"><span class="h3">Tumor volume measurement</span><span class="headingEndMark"> — </span>Estimates of tumor volume may prove more useful than planar methods of tumor measurement in evaluating tumor response. In a retrospective study of 45 HCCs, the largest tumor diameter based upon three-dimensional measurements was significantly different than the diameter based upon conventional two-dimensional measurements [<a href="#rid99">99</a>]. Where available, volumetric evaluation of HCC and its necrotic component offers the most comprehensive anatomic evaluation for determining treatment response [<a href="#rid100">100</a>], and it is more accurate and reproducible than two-dimensional analysis [<a href="#rid99">99,101</a>]. Volumetric quantification is particularly helpful in cases in which areas of necrosis are heterogeneously distributed within the tumor, making it difficult to assess using mRECIST for HCC guidelines.</p><p>Although semiautomatic volumetric evaluation is feasible in clinical settings of HCC treated with locoregional therapies [<a href="#rid102">102</a>] and <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid103">103</a>], volumetry has not yet been incorporated into any of the commonly used viability or size-based response criteria in HCC.</p><p class="headingAnchor" id="H524734698"><span class="h3">Functional imaging</span><span class="headingEndMark"> — </span>In contrast to anatomic imaging, functional imaging provides information on tumor viability, cellularity, vascularity, and metabolism [<a href="#rid104">104</a>]. In general, changes such as these can be detected earlier than anatomic changes and are more accurate in assessing treatment response after nonsurgical locoregional ablative therapy or systemic therapy of HCC [<a href="#rid105">105</a>]. Contrast enhancement on CT or MRI is a good marker for function, as is diffusion-weighted MRI. (See <a class="local">'MRI'</a> above.)</p><p>Other than these methods, functional imaging of response to HCC therapy can also be achieved by quantifying liver perfusion using fluorodeoxyglucose-positron emission tomography imaging, perfusion CT, and multiparametric MRI using gadolinium contrast with quantitative perfusion and diffusion-weighted imaging [<a href="#rid106">106-118</a>]. While functional imaging is promising, none of these modalities have been validated for clinical use. Their role as novel markers for response to nonsurgical locoregional or systemic therapy in HCC awaits evaluation in prospective studies.</p><p class="headingAnchor" id="H2771423976"><span class="h1">GUIDELINES FOR POST-TREATMENT IMAGING</span><span class="headingEndMark"> — </span>For most patients, we perform dynamic (contrast-enhanced) cross-sectional imaging with either computed tomography or magnetic resonance imaging approximately eight weeks after the start of systemic therapy and four weeks after nonsurgical locoregional therapy for HCC. However, if radioembolization or stereotactic body radiation therapy was undertaken, we delay the first assessment until three months. In patients whose disease is treated with radiation and imaged earlier than three months, it may be confusing to interpret radiographic studies because they often demonstrate arterial hyperenhancement both in the tumor and other non-target liver regions. It may take three to six months to observe the optimal response [<a href="#rid119">119,120</a>]. </p><p>For most patients, we then continue monitoring for recurrent or new disease every three months for at least the first year. For patients treated with transarterial chemoembolization (TACE), imaging to assess for treatment response is offered at one month post treatment completion and then at three-month intervals subsequently for one year. For patients treated with transarterial radioembolization (TARE) and stereotactic body radiation therapy (SBRT), imaging is generally performed three months after treatment and at three-month intervals for one year. </p><p>If there has been no recurrence of disease after a year, we then perform the same imaging every six months. After two years with no evidence of disease recurrence some institutions, including ours, revert back to standard HCC surveillance with cross-sectional imaging and alpha-fetoprotein (AFP) assay every six months. At many institutions, cross-sectional imaging every six months is continued beyond the two-year cutoff, given the continued elevated risk for HCC in these patients. The use of ultrasound (US) in this situation is controversial, and many believe that the risk remains sufficiently high that periodic cross-sectional imaging should be continued beyond two years. (See  <a class="medical medical_review" href="/d/html/3583.html" rel="external">"Surveillance for hepatocellular carcinoma in adults", section on 'Summary and recommendations'</a>.)</p><p>These recommendations are consistent with guidelines for post-treatment imaging after systemic therapy or nonsurgical locoregional therapy from the European Association for the Study of the Liver (EASL) [<a href="#rid121">121</a>]. Specific recommendations for post-treatment imaging are also provided in the consensus-based guidelines of the National Comprehensive Cancer Network [<a href="#rid122">122</a>].</p><p class="headingAnchor" id="H4282818431"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/119333.html" rel="external">"Society guideline links: Hepatocellular carcinoma"</a>.)</p><p class="headingAnchor" id="H850019"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methods for response assessment</strong> – Adequate response assessment of hepatocellular cancer (HCC) is a requirement for clinical evaluation of the effect of nonsurgical locoregional and systemic therapies, and for use as endpoints in clinical trials as a surrogate for survival. (See <a class="local">'Techniques for assessment of treatment response'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Radiographic assessment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For most patients, the efficacy of nonsurgical local ablation therapy or systemic therapy is assessed by dynamic contrast-enhanced CT or contrast-enhanced MRI. (See <a class="local">'Imaging studies'</a> above.)</p><p></p><p class="bulletIndent2">Following nonsurgical local therapy, MRI is generally preferred over CT due to its inherent superior tissue contrast resolution and sensitivity for detection of both the lesion and associated post-treatment changes. We use the American College of Radiology Liver Reporting and Data System (LI-RADS) treatment response algorithm after locoregional therapies for HCC  (<a class="graphic graphic_algorithm graphicRef130552" href="/d/graphic/130552.html" rel="external">algorithm 2</a>). The most important feature of this treatment response algorithm is persistent lesion contrast enhancement and washout. (See <a class="local">'LI-RADS algorithm'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency of imaging </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We perform the first cross-sectional imaging study four to eight weeks after nonsurgical locoregional therapy. For most patients, we continue imaging monitoring every three months for at least the first year. Thereafter, either cross-sectional imaging could be performed every six months. (See <a class="local">'Guidelines for post-treatment imaging'</a> above.)</p><p></p><p class="bulletIndent2">Radiographic responses may be delayed in patients treated with radioembolization or stereotactic body radiation therapy, and we delay the first post-treatment radiographic assessment for disease response to three months. (See <a class="local">'Guidelines for post-treatment imaging'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients receiving systemic therapy, radiographic assessment for tumor response is typically carried out after the initial six to eight weeks of therapy, and then every two to three months thereafter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> <strong>serum AFP</strong> – For the subset of patients with an elevated alpha-fetoprotein (AFP), this marker can be useful to follow response; elevations may precede radiographic imaging changes of progression by several weeks or months. (See <a class="local">'Tumor markers'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response criteria for hypervascular HCC </strong>–<strong> </strong>For patients with typical hypervascular tumors who are treated with nonsurgical locoregional or systemic therapy, response criteria that assess tumor viability by cross-sectional imaging are typically preferred over those that measure tumor dimension. Response criteria based on tumor dimension do not incorporate tumor viability and the extent of necrosis caused by locoregional or systemic therapies. (See <a class="local">'Measuring tumor dimensions versus tumor viability'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Following systemic therapy</strong> – For patients treated with systemic therapy, treatment response is typically classified using either the modified Response Evaluation Criteria In Solid Tumor for HCC (mRECIST)  (<a class="graphic graphic_table graphicRef58792" href="/d/graphic/58792.html" rel="external">table 1</a>), or unidimensional Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1)  (<a class="graphic graphic_table graphicRef74693" href="/d/graphic/74693.html" rel="external">table 2</a>). (See <a class="local">'Modified RECIST for HCC'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Following immunotherapy</strong> – Patients treated with immunotherapy are assessed using consensus based criteria for response to immunotherapy (iRECIST)  (<a class="graphic graphic_table graphicRef115573" href="/d/graphic/115573.html" rel="external">table 3</a>). (See <a class="local">'Response criteria for immunotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Following locoregional therapy</strong> – For patients treated with locoregional therapy, treatment response is classified using LI-RADS  (<a class="graphic graphic_algorithm graphicRef130552" href="/d/graphic/130552.html" rel="external">algorithm 2</a>). (See <a class="local">'LI-RADS algorithm'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Response criteria for nonenhancing atypical HCCs</strong> – Standard RECIST<strong> </strong>1.1 guidelines are used for nonenhancing atypical lesions, including poorly differentiated HCC and diffuse-type HCC. Radiographic response criteria that assess tumor viability cannot be used for atypical HCC. (See <a class="local">'Response Evaluation Criteria In Solid Tumor (RECIST)'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022; 76:681.</a></li><li><a class="nounderline abstract_t">Wald C, Russo MW, Heimbach JK, et al. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology 2013; 266:376.</a></li><li><a class="nounderline abstract_t">Earls JP, Rofsky NM, DeCorato DR, et al. Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging: optimization with a test examination and a power injector. Radiology 1997; 202:268.</a></li><li><a class="nounderline abstract_t">Ringe KI, Husarik DB, Sirlin CB, Merkle EM. Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010; 195:13.</a></li><li><a class="nounderline abstract_t">Cruite I, Schroeder M, Merkle EM, Sirlin CB. Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 2010; 195:29.</a></li><li><a class="nounderline abstract_t">Watanabe H, Kanematsu M, Goshima S, et al. Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy? AJR Am J Roentgenol 2012; 198:589.</a></li><li><a class="nounderline abstract_t">Yoon JH, Lee EJ, Cha SS, et al. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol 2010; 21:348.</a></li><li><a class="nounderline abstract_t">Schima W, Ba-Ssalamah A, Kurtaran A, et al. Post-treatment imaging of liver tumours. Cancer Imaging 2007; 7 Spec No A:S28.</a></li><li><a class="nounderline abstract_t">Kim S, Mannelli L, Hajdu CH, et al. Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 2010; 31:348.</a></li><li><a class="nounderline abstract_t">Kamel IR, Bluemke DA, Eng J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 2006; 17:505.</a></li><li><a class="nounderline abstract_t">Kloeckner R, Otto G, Biesterfeld S, et al. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33:532.</a></li><li><a class="nounderline abstract_t">Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007; 188:1622.</a></li><li><a class="nounderline abstract_t">Hamstra DA, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007; 25:4104.</a></li><li><a class="nounderline abstract_t">Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11:102.</a></li><li><a class="nounderline abstract_t">Altenbernd J, Heusner TA, Ringelstein A, et al. Dual-energy-CT of hypervascular liver lesions in patients with HCC: investigation of image quality and sensitivity. Eur Radiol 2011; 21:738.</a></li><li><a class="nounderline abstract_t">Silva AC, Morse BG, Hara AK, et al. Dual-energy (spectral) CT: applications in abdominal imaging. Radiographics 2011; 31:1031.</a></li><li><a class="nounderline abstract_t">Lee SH, Lee JM, Kim KW, et al. Dual-energy computed tomography to assess tumor response to hepatic radiofrequency ablation: potential diagnostic value of virtual noncontrast images and iodine maps. Invest Radiol 2011; 46:77.</a></li><li><a class="nounderline abstract_t">Curley SA, Izzo F, Ellis LM, et al. Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 2000; 232:381.</a></li><li><a class="nounderline abstract_t">Riaz A, Ryu RK, Kulik LM, et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009; 27:5734.</a></li><li><a class="nounderline abstract_t">Memon K, Kulik L, Lewandowski RJ, et al. Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis. J Hepatol 2012; 56:1112.</a></li><li><a class="nounderline abstract_t">Spira D, Fenchel M, Lauer UM, et al. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol 2011; 18:89.</a></li><li><a class="nounderline abstract_t">Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol 2012; 57:101.</a></li><li><a class="nounderline abstract_t">Chan SL, Mo FK, Johnson PJ, et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009; 27:446.</a></li><li><a class="nounderline abstract_t">Vora SR, Zheng H, Stadler ZK, et al. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist 2009; 14:717.</a></li><li><a class="nounderline abstract_t">Shao YY, Lin ZZ, Hsu C, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010; 116:4590.</a></li><li><a class="nounderline abstract_t">Yau T, Yao TJ, Chan P, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 2011; 16:1270.</a></li><li><a class="nounderline abstract_t">Chau I, Park JO, Ryoo BY, et al. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study. Br J Cancer 2018; 119:19.</a></li><li><a class="nounderline abstract_t">Kelley RK, Meyer T, Rimassa L, et al. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2020; 26:4795.</a></li><li class="breakAll">Zhu AX, et al. Alpha-fetoprotein kinetics as a potential surrogate biomarker in patients with hepatocellular carcinoma treated with atezolizumab + bevacizumab (abstract 0-18).  data presented at the 2020 virtual  meeting of the International Liver Cancer Asssociation, 11-13 September 2020. Abstract available online at https://www.ilca2020.org/wp-content/uploads/2020/09/ABSTRACTS-2020-1.pdf (Accessed on September 15, 2021).</li><li><a class="nounderline abstract_t">Kawaoka T, Aikata H, Murakami E, et al. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Oncology 2012; 83:192.</a></li><li><a class="nounderline abstract_t">Nakano M, Tanaka M, Kuromatsu R, et al. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. Oncology 2013; 84:108.</a></li><li><a class="nounderline abstract_t">Park WH, Shim JH, Han SB, et al. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2012; 23:927.</a></li><li><a class="nounderline abstract_t">Nakazawa T, Hidaka H, Takada J, et al. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2013; 25:683.</a></li><li><a class="nounderline abstract_t">Lee YK, Kim SU, Kim DY, et al. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer 2013; 13:5.</a></li><li><a class="nounderline abstract_t">Tsuchiya K, Asahina Y, Matsuda S, et al. Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer 2014; 120:229.</a></li><li><a class="nounderline abstract_t">Llovet JM, Peña CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18:2290.</a></li><li><a class="nounderline abstract_t">Chen VL, Xu D, Wicha MS, et al. Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review. Clin Gastroenterol Hepatol 2020; 18:2879.</a></li><li><a class="nounderline abstract_t">Park S, Lee EJ, Rim CH, Seong J. Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma. Yonsei Med J 2018; 59:470.</a></li><li><a class="nounderline abstract_t">Alunni-Fabbroni M, Rönsch K, Huber T, et al. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. J Transl Med 2019; 17:328.</a></li><li class="breakAll">Hsu C-H, Lu S, Abbas A, et al. Longitudinal and personalized detection of circulating tumor DNA (ctDNA) for monitoring efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma (HCC) (abstract). J Clin Oncol 2020 38:15_suppl, 3531. Abstract available online at https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3531 (Accessed on September 15, 2021).</li><li class="breakAll">Du X, Li Z, Zhang H. Detection of early recurrence in HCC patients after TACE treatment with plasma cfDNA (abstr). J Clin Oncol (2018) 36(15_suppl):e16146.</li><li><a class="nounderline abstract_t">Li Z, Xiao D, Li X, et al. Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA. Eur J Gastroenterol Hepatol 2019; 31:885.</a></li><li><a class="nounderline abstract_t">Takayasu K, Arii S, Matsuo N, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol 2000; 175:699.</a></li><li><a class="nounderline abstract_t">Kwan SW, Fidelman N, Ma E, et al. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl 2012; 18:727.</a></li><li><a class="nounderline abstract_t">Kim HC, Chung JW, Lee W, et al. Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiographics 2005; 25 Suppl 1:S25.</a></li><li><a class="nounderline abstract_t">Yue J, Mauxion T, Reyes DK, et al. Comparison of quantitative Y-90 SPECT and non-time-of-flight PET imaging in post-therapy radioembolization of liver cancer. Med Phys 2016; 43:5779.</a></li><li><a class="nounderline abstract_t">Nakazawa T, Kokubu S, Shibuya A, et al. Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin. AJR Am J Roentgenol 2007; 188:480.</a></li><li><a class="nounderline abstract_t">Park MH, Rhim H, Kim YS, et al. Spectrum of CT findings after radiofrequency ablation of hepatic tumors. Radiographics 2008; 28:379.</a></li><li><a class="nounderline abstract_t">Kim YS, Rhim H, Lim HK. Imaging after radiofrequency ablation of hepatic tumors. Semin Ultrasound CT MR 2009; 30:49.</a></li><li><a class="nounderline abstract_t">Kim SK, Lim HK, Kim YH, et al. Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings. Radiographics 2003; 23:107.</a></li><li><a class="nounderline abstract_t">Kierans AS, Elazzazi M, Braga L, et al. Thermoablative treatments for malignant liver lesions: 10-year experience of MRI appearances of treatment response. AJR Am J Roentgenol 2010; 194:523.</a></li><li><a class="nounderline abstract_t">Khankan AA, Murakami T, Onishi H, et al. Hepatocellular carcinoma treated with radio frequency ablation: an early evaluation with magnetic resonance imaging. J Magn Reson Imaging 2008; 27:546.</a></li><li><a class="nounderline abstract_t">Lim HK, Choi D, Lee WJ, et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology 2001; 221:447.</a></li><li><a class="nounderline abstract_t">Keppke AL, Salem R, Reddy D, et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am J Roentgenol 2007; 188:768.</a></li><li><a class="nounderline abstract_t">Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009; 49:1185.</a></li><li><a class="nounderline abstract_t">Gabr A, Abouchaleh N, Ali R, et al. Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma. J Vasc Interv Radiol 2018; 29:1502.</a></li><li><a class="nounderline abstract_t">Ibrahim SM, Nikolaidis P, Miller FH, et al. Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 2009; 34:566.</a></li><li><a class="nounderline abstract_t">Aslam A, Do RKG, Kambadakone A, et al. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol 2020; 12:738.</a></li><li><a class="nounderline abstract_t">Price TR, Perkins SM, Sandrasegaran K, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer 2012; 118:3191.</a></li><li><a class="nounderline abstract_t">Sanuki N, Takeda A, Mizuno T, et al. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. AJR Am J Roentgenol 2013; 201:W812.</a></li><li><a class="nounderline abstract_t">Park MJ, Kim SY, Yoon SM, et al. Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed tomography. PLoS One 2014; 9:e90327.</a></li><li><a class="nounderline abstract_t">Horger M, Lauer UM, Schraml C, et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer 2009; 9:208.</a></li><li><a class="nounderline abstract_t">Schraml C, Schwenzer NF, Martirosian P, et al. Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol 2009; 193:W301.</a></li><li><a class="nounderline abstract_t">Salvaggio G, Furlan A, Agnello F, et al. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results. Radiol Med 2014; 119:215.</a></li><li><a class="nounderline abstract_t">Kim MJ, Choi JI, Lee JS, Park JW. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 26:1201.</a></li><li><a class="nounderline abstract_t">Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.</a></li><li><a class="nounderline abstract_t">Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.</a></li><li class="breakAll">WHO Handbook for Reporting Results of Cancer Treatment, World Health Organization (Ed), WHO Offset Publication No. 48, Geneva, Switzerland 1979.</li><li><a class="nounderline abstract_t">Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207.</a></li><li><a class="nounderline abstract_t">Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378.</a></li><li><a class="nounderline abstract_t">Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25.</a></li><li><a class="nounderline abstract_t">Bruix J, Reig M, Rimola J, et al. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 2011; 54:2238.</a></li><li><a class="nounderline abstract_t">Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 2009; 115:616.</a></li><li><a class="nounderline abstract_t">Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010; 303:1062.</a></li><li><a class="nounderline abstract_t">Duke E, Deng J, Ibrahim SM, et al. Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization. J Vasc Interv Radiol 2010; 21:515.</a></li><li><a class="nounderline abstract_t">Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55:1309.</a></li><li><a class="nounderline abstract_t">Prajapati HJ, Spivey JR, Hanish SI, et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol 2013; 24:965.</a></li><li><a class="nounderline abstract_t">Jung ES, Kim JH, Yoon EL, et al. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol 2013; 58:1181.</a></li><li><a class="nounderline abstract_t">Shim JH, Lee HC, Kim SO, et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012; 262:708.</a></li><li><a class="nounderline abstract_t">Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118:147.</a></li><li><a class="nounderline abstract_t">Kim BK, Kim KA, Park JY, et al. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer 2013; 49:826.</a></li><li><a class="nounderline abstract_t">Lencioni R. New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma. Clin Cancer Res 2013; 19:1312.</a></li><li><a class="nounderline abstract_t">Memon K, Kulik L, Lewandowski RJ, et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 2011; 141:526.</a></li><li><a class="nounderline abstract_t">Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208.</a></li><li><a class="nounderline abstract_t">Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421.</a></li><li><a class="nounderline abstract_t">Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52.</a></li><li><a class="nounderline abstract_t">Kudo M. Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma. Liver Cancer 2019; 8:73.</a></li><li class="breakAll">Ducreux M, Zhu AX, Cheng A-L. et al. IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) (abstr). J Clin Oncol 2021; 39:15_;Suppl; 4071. Abstract available online at https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.4071 (Accessed on September 15, 2021).</li><li><a class="nounderline abstract_t">Kudo S, Finn RS, Qin S, et al. Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib. J Clin Oncol 2019; 37S: ASCO #186.</a></li><li><a class="nounderline abstract_t">Kim HI, Lim J, Shim JH. Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2022; 148:2069.</a></li><li><a class="nounderline abstract_t">Shao YY, Liu TH, Hsu C, et al. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver Int 2019; 39:2184.</a></li><li><a class="nounderline abstract_t">Lee PC, Chao Y, Chen MH, et al. Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2020; 12.</a></li><li><a class="nounderline abstract_t">Zhu AX, Dayyani F, Yen CJ, et al. Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clin Cancer Res 2022; 28:3537.</a></li><li><a class="nounderline abstract_t">Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology 2015; 275:97.</a></li><li><a class="nounderline abstract_t">Bae JS, Lee JM, Yoon JH, et al. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI. Radiology 2021; 299:336.</a></li><li><a class="nounderline abstract_t">Chaudhry M, McGinty KA, Mervak B, et al. The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma. Radiology 2020; 294:320.</a></li><li><a class="nounderline abstract_t">Shaffer KM, Parikh MR, Runge TM, et al. Renal safety of intravenous gadolinium-enhanced magnetic resonance imaging in patients awaiting liver transplantation. Liver Transpl 2015; 21:1340.</a></li><li><a class="nounderline abstract_t">Kielar A, Fowler KJ, Lewis S, et al. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY) 2018; 43:218.</a></li><li><a class="nounderline abstract_t">Galizia MS, Töre HG, Chalian H, Yaghmai V. Evaluation of hepatocellular carcinoma size using two-dimensional and volumetric analysis: effect on liver transplantation eligibility. Acad Radiol 2011; 18:1555.</a></li><li><a class="nounderline abstract_t">Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100:698.</a></li><li><a class="nounderline abstract_t">Chalian H, Tochetto SM, Töre HG, et al. Hepatic tumors: region-of-interest versus volumetric analysis for quantification of attenuation at CT. Radiology 2012; 262:853.</a></li><li><a class="nounderline abstract_t">Lin M, Pellerin O, Bhagat N, et al. Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization. J Vasc Interv Radiol 2012; 23:1629.</a></li><li><a class="nounderline abstract_t">Bargellini I, Scionti A, Mismas V, et al. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward? Oncology 2014; 86:191.</a></li><li><a class="nounderline abstract_t">Alonzi R, Hoskin P. Functional imaging in clinical oncology: magnetic resonance imaging- and computerised tomography-based techniques. Clin Oncol (R Coll Radiol) 2006; 18:555.</a></li><li><a class="nounderline abstract_t">Yaghmai V, Besa C, Kim E, et al. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. AJR Am J Roentgenol 2013; 201:80.</a></li><li><a class="nounderline abstract_t">Sahani DV, Holalkere NS, Mueller PR, Zhu AX. Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. Radiology 2007; 243:736.</a></li><li><a class="nounderline abstract_t">Jiang T, Kambadakone A, Kulkarni NM, et al. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol 2012; 47:11.</a></li><li><a class="nounderline abstract_t">Kim H, Keene KS, Sarver DB, et al. Quantitative perfusion- and diffusion-weighted magnetic resonance imaging of gastrointestinal cancers treated with multikinase inhibitors: a pilot study. Gastrointest Cancer Res 2014; 7:75.</a></li><li><a class="nounderline abstract_t">Chen X, Xiao E, Shu D, et al. Evaluating the therapeutic effect of hepatocellular carcinoma treated with transcatheter arterial chemoembolization by magnetic resonance perfusion imaging. Eur J Gastroenterol Hepatol 2014; 26:109.</a></li><li><a class="nounderline abstract_t">Koh DM. Science to practice: can intravoxel incoherent motion diffusion-weighted MR imaging be used to assess tumor response to antivascular drugs? Radiology 2014; 272:307.</a></li><li><a class="nounderline abstract_t">Ahn SJ, Park MS, Kim KA, et al. ¹⁸F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study. PLoS One 2013; 8:e71571.</a></li><li><a class="nounderline abstract_t">Ma W, Jia J, Wang S, et al. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics 2014; 4:736.</a></li><li><a class="nounderline abstract_t">Sabet A, Ahmadzadehfar H, Bruhman J, et al. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET. Nuklearmedizin 2014; 53:39.</a></li><li><a class="nounderline abstract_t">Kucuk ON, Soydal C, Araz M, et al. Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT. Clin Nucl Med 2013; 38:e283.</a></li><li><a class="nounderline abstract_t">Morsbach F, Sah BR, Spring L, et al. Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques. Eur Radiol 2014; 24:1455.</a></li><li><a class="nounderline abstract_t">Reiner CS, Morsbach F, Sah BR, et al. Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion. J Vasc Interv Radiol 2014; 25:747.</a></li><li><a class="nounderline abstract_t">Wang Q, Shi G, Wang L, et al. Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study. Br J Radiol 2014; 87:20130695.</a></li><li><a class="nounderline abstract_t">Sacco R, Faggioni L, Bargellini I, et al. Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study. Dig Liver Dis 2013; 45:776.</a></li><li><a class="nounderline abstract_t">Spina JC, Hume I, Pelaez A, et al. Expected and Unexpected Imaging Findings after 90Y Transarterial Radioembolization for Liver Tumors. Radiographics 2019; 39:578.</a></li><li><a class="nounderline abstract_t">Mendiratta-Lala M, Masch WR, Shampain K, et al. MRI Assessment of Hepatocellular Carcinoma after Local-Regional Therapy: A Comprehensive Review. Radiol Imaging Cancer 2020; 2:e190024.</a></li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="ef8a8e9c83808989868c8aaf8a8e9c83808989868c8ac18a9a">[email protected]</span>, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69:182.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li></ol></div><div id="topicVersionRevision">Topic 83809 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34801630" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23362092" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988222" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging: optimization with a test examination and a power injector.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20566794" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20566795" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22357997" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20116285" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17921098" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Post-treatment imaging of liver tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20099348" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16567675" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19847482" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17515386" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Diffusion-weighted MRI in the body: applications and challenges in oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17827460" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19186405" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20936520" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Dual-energy-CT of hypervascular liver lesions in patients with HCC: investigation of image quality and sensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768237" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Dual-energy (spectral) CT: applications in abdominal imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20856125" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dual-energy computed tomography to assess tumor response to hepatic radiofrequency ablation: potential diagnostic value of virtual noncontrast images and iodine maps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10973388" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19805671" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22245905" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Alpha-fetoprotein response correlates with EASL response and survival in solitary hepatocellular carcinoma treated with transarterial therapies: a subgroup analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926315" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22414760" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19064965" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19581525" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20572033" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21885876" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29808014" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32636319" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32636319" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22890083" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Evaluation of the mRECIST andα-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23147476" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22633621" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23395995" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Early increase inα-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23282286" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Prognostic value ofα-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24122122" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22374331" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32289533" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Utility of Liquid Biopsy Analysis in Detection of Hepatocellular Carcinoma, Determination of Prognosis, and Disease Monitoring: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29749129" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31570105" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31570105" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31570105" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30807446" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Early recurrence detected in hepatocellular carcinoma patients after transcatheter arterial chemoembolization treatment with plasma cell-free DNA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10954453" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22344899" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16227494" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27782730" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Comparison of quantitative Y-90 SPECT and non-time-of-flight PET imaging in post-therapy radioembolization of liver cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17242258" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18349446" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Spectrum of CT findings after radiofrequency ablation of hepatic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19358437" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Imaging after radiofrequency ablation of hepatic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12533646" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Hepatocellular carcinoma treated with radio-frequency ablation: spectrum of imaging findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20093619" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Thermoablative treatments for malignant liver lesions: 10-year experience of MRI appearances of treatment response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18183580" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Hepatocellular carcinoma treated with radio frequency ablation: an early evaluation with magnetic resonance imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11687689" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17312067" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19133645" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30268638" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Outcomes of Surgical Resection after Radioembolization for Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18777189" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Radiologic findings following Y90 radioembolization for primary liver malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33200013" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22025126" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24261388" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24587326" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19558720" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19770299" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24297581" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21371120" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655437" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19097774" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19097774" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7459811" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Reporting results of cancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18650514" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Sorafenib in advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19095497" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21932394" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19117042" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20233824" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20172741" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Agreement between competing imaging measures of response of hepatocellular carcinoma to yttrium-90 radioembolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21703196" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23223331" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23395691" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22187634" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21713764" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22995582" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23382112" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : New data supporting modified RECIST (mRECIST) for Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21664356" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16250051" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Management of hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11592607" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20175033" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31019898" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31019898" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Objective Response by mRECIST Is an Independent Prognostic Factor of Overall Survival in Systemic Therapy for Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Analysis of survival and objective response (OR) in patients with hepatocellular carcinoma in a phase III study of lenvatinib</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34459972" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31400295" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31940757" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35435967" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25559230" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33650901" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31845843" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25786913" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Renal safety of intravenous gadolinium-enhanced magnetic resonance imaging in patients awaiting liver transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28780679" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21962475" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Evaluation of hepatocellular carcinoma size using two-dimensional and volumetric analysis: effect on liver transplantation eligibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18477802" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Design and endpoints of clinical trials in hepatocellular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22357887" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Hepatic tumors: region-of-interest versus volumetric analysis for quantification of attenuation at CT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23177109" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Quantitative and volumetric European Association for the Study of the Liver and Response Evaluation Criteria in Solid Tumors measurements: feasibility of a semiautomated software method to assess tumor response after transcatheter arterial chemoembolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24800837" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16969988" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Functional imaging in clinical oncology: magnetic resonance imaging- and computerised tomography-based techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23789661" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17517931" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21512396" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25276260" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Quantitative perfusion- and diffusion-weighted magnetic resonance imaging of gastrointestinal cancers treated with multikinase inhibitors: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24284371" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Evaluating the therapeutic effect of hepatocellular carcinoma treated with transcatheter arterial chemoembolization by magnetic resonance perfusion imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25058129" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Science to practice: can intravoxel incoherent motion diffusion-weighted MR imaging be used to assess tumor response to antivascular drugs?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23940769" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : ¹⁸F-FDG PET metabolic parameters and MRI perfusion and diffusion parameters in hepatocellular carcinoma: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24883123" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24777354" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23531737" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Prognostic importance of 18F-FDG uptake pattern of hepatocellular cancer patients who received SIRT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24817083" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Perfusion CT best predicts outcome after radioembolization of liver metastases: a comparison of radionuclide and CT imaging techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24630751" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24452058" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23578581" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30844345" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Expected and Unexpected Imaging Findings after 90Y Transarterial Radioembolization for Liver Tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33778692" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : MRI Assessment of Hepatocellular Carcinoma after Local-Regional Therapy: A Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29628281" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
